Posts in Uncategorized

The SoHO Regulation: Preparing for the New EU Rules on Blood, Tissues and Cells

Regulation (EU) 2024/1938 on substances of human origin (SoHO) was published in the Official Journal on 17 July 2024 and applies from 7 August 2027,[…]

Herbal Medicinal Products in the EU: Traditional Use Registration Versus Well-Established Use

Herbal products sit on a regulatory boundary. Positioned as food supplements, they cannot make medicinal claims. Positioned as medicines, they need an authorisation or a[…]

Companion Diagnostics Under the IVDR: Aligning the Test and the Medicine

Targeted therapies increasingly depend on a test that decides which patients should receive them. Under the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746, that[…]

The European Health Data Space: What Regulation (EU) 2025/327 Means for Pharmaceutical Companies

The European Health Data Space Regulation, Regulation (EU) 2025/327, entered into force on 26 March 2025. Its obligations apply in stages from 2027 to 2035,[…]

ICH Q12 in the Revised EU Variations Framework: Making PACMPs and Established Conditions Work

Since 15 January 2026, every new variation submitted in the EU has been assessed against the revised Variations Guidelines that accompany Regulation (EU) 2024/1701. The[…]

Package Leaflet User Testing: Proving Patients Can Find and Understand What Matters

Every package leaflet submitted in the EU must reflect the results of consultation with target patient groups. For many marketing authorisation applicants, that consultation means[…]

Biosimilar Opinions in October 2026: Ranibizumab and Filgrastim Enter the Pipeline to Market

Two biosimilars received positive CHMP opinions in October 2026: Fovlussea (ranibizumab) for wet age-related macular degeneration and other visual impairments, and Neuzafy (filgrastim) for neutropenia.[…]

Extensions of Indication: Five Positive Opinions in October and the Extra Year of Market Protection

The October 2026 CHMP meeting recommended five extensions of indication, including for Talvey, Tryngolza, Tukysa, Kyinsu and a pandemic influenza H5N1 vaccine. EMA counts 97[…]

Preparing for the EU Pharma Reform: A Practical Readiness Checklist for Marketing Authorisation Holders

With the reform of EU pharmaceutical legislation moving towards publication, companies have a window to prepare. A phased approach avoids both premature spending and last-minute[…]

Regulatory Sandboxes and Antimicrobial Vouchers: Early-Application Provisions of the EU Reform

Most of the EU pharmaceutical reform will apply about two years after entry into force, but some provisions are expected to take effect immediately. Published[…]